Project Grant R01HL172449
Award Date
8/23/24
Completion Date
5/31/28
Dollars Obligated
$1.6M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94304, USA
Similar Awards
This $658,885 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to advance the fundamental understanding of the molecular mechanisms governing the development of pulmonary arterial hypertension (PAH). The research will utilize a combination of pulmonary arterial endothelial cell cultures and animal PAH models to: Determine how the protein factor Response Gene to Complement 32 (RGC-32) regulates...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,505,110 to The Leland Stanford Junior University to comprehensively characterize the cellular and molecular features of human pulmonary neuroendocrine cells (PNECs), their stem cells, and niches. The key objectives are to 1) map the innervation and molecular subtypes of human PNECs, 2) identify functionally distinct PNEC stem cells and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $244,589 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Research Foundation For The State University Of New York (RF SUNY) to conduct research on the role of vascular smooth muscle VPS34 in pulmonary arterial hypertension (PAH). The research aims to examine the status and regulation of VPS34 in the PAH pulmonary vasculature, determine the impact of VPS34 on the proliferation and survival of PAH...
The University of California, Los Angeles (UCLA) was awarded a $2,323,125.00 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The grant supports research focused on understanding the role of the RNA-binding protein ZFP36 in regulating DNA repair and cell proliferation in pulmonary arterial hypertension (PAH). Key objectives include utilizing computational biology to identify ZFP36 target genes involved in...
This federal Project Grant award for $717,246.00, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to elucidate the molecular mechanisms underlying cardiovascular toxicity induced by proteasome inhibitor cancer drugs, particularly carfilzomib. The research will leverage a mouse model of multiple myeloma, human induced pluripotent stem cells, CRISPR screening, single-cell RNA sequencing, and antisense...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,806,634 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of California, San Diego to study the NOTCH3 extracellular domain (NOTCH3 ECD) as a serum biomarker for pulmonary arterial hypertension (PAH). The goal is to determine if NOTCH3 ECD levels in patient serum can reliably predict PAH disease progression and severity, regardless of drug regimens. The research aims to develop a simple blood test...
The federal Project Grant award R03HL172985, totaling $131,485, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The award supports research to understand proline dysregulation in pulmonary artery endothelial cells, with a focus on the role of C-terminal Src kinase (CSK) and Src-dependent regulation of proline metabolism in early-stage pulmonary arterial hypertension (PAH). The research aims to...
This $2,130,422 project grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a comprehensive evaluation of lean muscle mass in patients with pulmonary arterial hypertension (PAH). The research project aims to: Characterize the endophenotype of PAH patients with low lean mass and identify the metabolomic signature associated with low lean mass, which may provide insight into novel pathways. Assess...
The National Heart Lung and Blood Institute (NHLBI) awarded a $164,700 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to study the role of mTOR hyperactivation in pulmonary vascular remodeling. The research aims to examine how mTOR activation in specific mesenchymal cell populations alters endothelial cell behavior and function, and how aberrant mTOR...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $596,809 to Emory University to conduct research on the role of the mitochondrial protein MitoNEET in pulmonary hypertension (PH). The primary goals are to define how MitoNEET regulates pulmonary artery smooth muscle cell (PASMC) mitochondrial function and proliferation in vitro, examine MitoNEET expression and function during...